
|Articles|March 1, 2004
CMS expands coverage for OPT with verteporfin
Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
AAO 2025: A study of retinal vasculitis events with intravitreal agents
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5


















































.png)


